Midatech Pharma PLC Completion of pre-clinical liver cancer programme
July 26 2017 - 2:01AM
RNS Non-Regulatory
TIDMMTPH
Midatech Pharma PLC
26 July 2017
26 July 2017
Midatech Pharma PLC
("Midatech", "Company" or "Group")
Completion of pre-clinical liver cancer programme
Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international
specialty pharmaceutical company focused on developing and
commercialising products in oncology, today announces the
successful completion of its pre-clinical programme for its
wholly-owned candidate MTD119 (previously MTR104) for advanced
liver cancer.
The pre-clinical programme included three subcutaneous or
orthotopic liver cancer xenograft models treated with the active
cytotoxic compound maytansine conjugated with Midatech's gold
nanoparticle (GNP) technology.
The studies demonstrated potent anti-tumour activity in vivo in
all efficacy models. Peak reduction in tumour growth due to MTD119
was more than six-fold (mean reduction more than three-fold)
compared to the current standard of care, sorafenib, and with
improved overall survival. The specific targeting of maytansine to
tumour cells by MTD119 also resulted in significantly improved
tolerability.
MTD119 is a targeted therapy treatment for advanced
hepatocellular carcinoma, which accounts for most liver cancers and
is the third leading cause of cancer deaths worldwide with almost
800,000 deaths in 2015(1) . Currently, 95% of cases are non-curable
and non-operable and median survival is less than one year, with
rare and short-lived successful outcomes with existing forms of
chemotherapy. Sorafenib (Nexavar) has projected 2018 annual sales
of almost $1.5 billion(2) .
MTD119 will now enter formal investigational new drug (IND)
application enabling studies, with completion expected in H1 2018.
This will be followed by an expected IND submission to the US Food
and Drug Administration for first in human studies to commence in
2018.
Commenting on the pre-clinical results, Dr Jim Phillips, CEO of
Midatech, said: "This is an important milestone in moving our
MTD119 compound towards the clinic as it represents Midatech's
first anti-cancer product using the Company's core proprietary GNP
technology platform. We are very encouraged by the results so far
and are focused on completing the formal IND safety studies over
the next six months and getting the product into first in human
studies in 2018."
(1) World Health Organization cancer fact sheet, February 2017,
www.who.int/mediacentre/factsheets/fs297/en
(2) www.fiercepharma.com/special-report/nexavar
- Ends -
For more information, please contact:
Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 841575
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate Finance
Freddy Crossley / Duncan Monteith
Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Cameron Standage
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Westwicke Partners (US Investor Relations)
Chris Brinzey
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC
Midatech is an international specialty pharmaceutical company
focused on oncology and other therapeutic areas with a US
commercial operation marketing four cancer care supportive
products, and co-promoting two others. Midatech's strategy is to
internally develop oncology products and collaborate with partners
in other therapy areas, and to drive growth both organically and
through strategic acquisitions. The Company's R&D activities
are supported by two breakthrough drug delivery technologies:
Q-Sphera for sustained release and our proprietary gold
nanoparticles. The Group, listed on AIM: MTPH and Nasdaq: MTP,
employs c.110 staff in four countries. For further company
information see: www.midatechpharma.com
Forward-Looking Statement
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States. Such forward-looking
statements include, but are not limited to, statements regarding
the ability of Midatech to successfully test, manufacture, produce
or commercialize products for conditions using the nanoparticle and
sustained release drug delivery platforms, and the ability for
products in development to achieve positive clinical results, and
the ability to meet or achieve timelines associated with
pre-clinical studies, clinical trials or regulatory submissions.
Any forward-looking statements are based on currently available
competitive, financial and economic data together with management's
views and assumptions regarding future events and business
performance as of the time the statements are made and are subject
to risks and uncertainties. We wish to caution you that there are
some known and unknown factors that could cause actual results to
differ materially from any future results, performance or
achievements expressed or implied by such forward-looking
statements.
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGUWUMUPMUAQ
(END) Dow Jones Newswires
July 26, 2017 02:01 ET (06:01 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024